Vinod Pullarkat

15.1k total citations · 2 hit papers
228 papers, 6.0k citations indexed

About

Vinod Pullarkat is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Vinod Pullarkat has authored 228 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 158 papers in Hematology, 82 papers in Public Health, Environmental and Occupational Health and 51 papers in Genetics. Recurrent topics in Vinod Pullarkat's work include Acute Myeloid Leukemia Research (89 papers), Acute Lymphoblastic Leukemia research (80 papers) and Chronic Myeloid Leukemia Treatments (46 papers). Vinod Pullarkat is often cited by papers focused on Acute Myeloid Leukemia Research (89 papers), Acute Lymphoblastic Leukemia research (80 papers) and Chronic Myeloid Leukemia Treatments (46 papers). Vinod Pullarkat collaborates with scholars based in United States, France and Australia. Vinod Pullarkat's co-authors include Stephen J. Forman, Ibrahim Aldoss, Courtney D. DiNardo, Jalaja Potluri, Keith W. Pratz, Brenda Chyla, Brian A. Jonas, Andrew H. Wei, Daniel A. Pollyea and Marina Konopleva and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Vinod Pullarkat

214 papers receiving 5.9k citations

Hit Papers

Venetoclax combined with ... 2018 2026 2020 2023 2018 2024 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
    2018 1.2k citations Courtney D. DiNardo, Keith W. Pratz et al. Blood profile →
  2. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
    2024 47 citations Keith W. Pratz, Courtney D. DiNardo et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Vinod Pullarkat 3.8k 1.9k 1.4k 1.3k 1.2k 228 6.0k
Nicolas Boissel 3.6k 1.0× 2.0k 1.1× 1.2k 0.9× 1.9k 1.5× 1.5k 1.3× 200 6.1k
Giuseppe Visani 4.0k 1.1× 2.2k 1.1× 2.0k 1.5× 981 0.8× 1.4k 1.2× 285 6.6k
Joseph O. Moore 3.3k 0.9× 1.8k 0.9× 1.5k 1.1× 1.2k 1.0× 1.9k 1.6× 148 6.6k
Ulrich Germing 5.4k 1.4× 2.4k 1.2× 2.4k 1.8× 971 0.8× 804 0.7× 252 7.0k
Donald Milligan 4.5k 1.2× 2.0k 1.0× 2.1k 1.6× 1.3k 1.0× 1.6k 1.4× 99 6.7k
Peter Westervelt 3.2k 0.9× 1.8k 0.9× 638 0.5× 721 0.6× 1.4k 1.2× 195 5.7k
Ghulam Mufti 4.7k 1.3× 1.2k 0.6× 2.0k 1.5× 790 0.6× 818 0.7× 101 5.8k
Carlo Dufour 2.9k 0.8× 1.1k 0.6× 871 0.6× 674 0.5× 1.2k 1.0× 174 5.1k
Ulrike Bacher 4.1k 1.1× 1.8k 1.0× 2.1k 1.5× 801 0.6× 1.1k 0.9× 281 5.7k
Michael Dworzak 3.6k 1.0× 1.2k 0.6× 654 0.5× 3.0k 2.4× 1.2k 1.0× 189 5.8k

Countries citing papers authored by Vinod Pullarkat

Since Specialization
Citations

This map shows the geographic impact of Vinod Pullarkat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vinod Pullarkat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vinod Pullarkat more than expected).

Fields of papers citing papers by Vinod Pullarkat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vinod Pullarkat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vinod Pullarkat. The network helps show where Vinod Pullarkat may publish in the future.

Co-authorship network of co-authors of Vinod Pullarkat

This figure shows the co-authorship network connecting the top 25 collaborators of Vinod Pullarkat. A scholar is included among the top collaborators of Vinod Pullarkat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vinod Pullarkat. Vinod Pullarkat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Huiyan, Bernard Tegtmeier, Jana Dickter, et al.. (2024). Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection. Open Forum Infectious Diseases. 11(8). ofae409–ofae409.
2.
Zhang, Jianying, Vinod Pullarkat, Vaibhav Agrawal, et al.. (2024). Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer. British Journal of Haematology. 205(1). 158–165. 1 indexed citations
3.
Dingli, David, Carlos de Castro, Austin Kulasekararaj, et al.. (2024). Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria. Hematology. 29(1). 2329030–2329030. 7 indexed citations
4.
Agrawal, Vaibhav, et al.. (2023). Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment. Frontiers in Oncology. 13. 1237031–1237031. 10 indexed citations
5.
Pullarkat, Vinod, Lisa S. Chen, Joycelynne Palmer, et al.. (2023). A phase 1 trial of 8‐chloro‐adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics. Cancer. 130(5). 727–739. 2 indexed citations
6.
Rosa, Corinna La, Ibrahim Aldoss, Dongyun Yang, et al.. (2023). CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients after Stem Cell Transplant. Transplantation and Cellular Therapy. 29(2). S68–S69. 1 indexed citations
7.
Rainone, Michael, Carolyn E. Behrendt, Saro Kasparian, et al.. (2023). HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia. Breast Cancer. 30(5). 796–801. 3 indexed citations
8.
9.
Pollyea, Daniel A., Keith W. Pratz, Andrew H. Wei, et al.. (2022). Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clinical Cancer Research. 28(24). 5272–5279. 75 indexed citations
10.
Konopleva, Marina, Michael J. Thirman, Keith W. Pratz, et al.. (2022). Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. Clinical Cancer Research. 28(13). 2744–2752. 59 indexed citations
11.
Stock, Wendy, Jae H. Park, Ashkan Emadi, et al.. (2021). Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study. Blood. 138(Supplement 1). 4406–4406. 1 indexed citations
12.
Ohanian, Maro, José A. Cancelas, Robertson D. Davenport, et al.. (2021). Freeze‐dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies. American Journal of Hematology. 97(3). 256–266. 13 indexed citations
13.
Nelson, Rebecca A., Ibrahim Aldoss, Vinod Pullarkat, et al.. (2021). Immunophenotype of acute lymphoblastic leukemia in minorities‐ analysis from the SEER database. Hematological Oncology. 40(1). 106–111. 3 indexed citations
14.
Yao, Janny M., Dongyun Yang, Mary C. Clark, et al.. (2021). Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Bone Marrow Transplantation. 57(2). 232–242. 3 indexed citations
15.
Cuker, Adam, Jenny M. Despotovic, Rachael F. Grace, et al.. (2020). Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. Research and Practice in Thrombosis and Haemostasis. 5(1). 69–80. 15 indexed citations
16.
Aldoss, Ibrahim, Jianying Zhang, Matthew Mei, et al.. (2020). Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia. American Journal of Hematology. 95(10). 1193–1199. 27 indexed citations
17.
Piatek, Caroline, Vinod Pullarkat, Imran Siddiqi, et al.. (2017). Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome. Acta Haematologica. 138(3). 129–137. 18 indexed citations
18.
19.
20.
Pullarkat, Vinod, Yashwant M. Deo, John S. Link, et al.. (1999). A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunology Immunotherapy. 48(1). 9–21. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolas Boissel Breakdown of academic impact, for papers by Giuseppe Visani Breakdown of academic impact, for papers by Joseph O. Moore Breakdown of academic impact, for papers by Ulrich Germing Breakdown of academic impact, for papers by Donald Milligan Breakdown of academic impact, for papers by Peter Westervelt Breakdown of academic impact, for papers by Ghulam Mufti Breakdown of academic impact, for papers by Carlo Dufour Breakdown of academic impact, for papers by Ulrike Bacher Breakdown of academic impact, for papers by Michael Dworzak
Rankless by CCL
2026